0
Deep & Emerging Tech·November 12, 2026·1 min read

Exclusive: Orakl Oncology raises $34m to test cancer drugs on ‘virtual patients’

Share

Virtual patient platforms compress early drug testing cycles and shift some value from wet labs to compute and modeling. If you're in oncology or adjacent tools, expect pressure to integrate with these simulation layers—or risk being sidelined in trial design and partner selection.